key: cord-0984868-6mk0txi8 authors: Subbarao, Kanta; Mahanty, Siddhartha title: Respiratory virus infections: Understanding COVID-19 date: 2020-05-20 journal: Immunity DOI: 10.1016/j.immuni.2020.05.004 sha: 8edf1dc1108f7b5416f232bac3953a14e9decf30 doc_id: 984868 cord_uid: 6mk0txi8 Respiratory viruses affect us throughout our lives, from infancy to old age, causing illnesses ranging from a common cold to severe pneumonia. They belong to several virus families, and although many features of infection with these diverse viruses are shared, some have unique characteristics. Here we explain what happens when we are infected by respiratory viruses, including SARS-CoV-2, which causes COVID-19. Respiratory viruses affect us throughout our lives, from infancy to old age, causing illnesses ranging from a common cold to severe pneumonia. They belong to several virus families and though several features of infections with these diverse viruses are shared, some have unique characteristics. Here we explain what happens when we are infected by respiratory viruses, including SARS-CoV-2, which causes COVID-19. infects the cells of the respiratory mucosa; this can occur when virus particles are inhaled or directly contact a mucosal surface of the nose or eyes. Infected individuals shed virus into the environment by coughing or sneezing, or even during quiet breathing. Virus shed during coughing and sneezing is often present in large droplets that fall out of the air within a short distance. If the virus falls on a surface and survives, it can be transmitted when someone touches the infected surface and then touches their nose, eyes or mouth. Virus is also spread by the airborne route in the form of small (<5µm) droplet nuclei that can remain suspended for long periods of time and can be inhaled into the lower respiratory tract. The relative contribution of different particle sizes and of direct contact versus airborne transmission as a means of spread differs among the respiratory viruses. Influenza viruses are spread by contact as well as by airborne transmission, but the mode of transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still being discussed. Some viruses are more fragile than others; for example, respiratory syncytial virus (RSV), the most important respiratory virus in early childhood does not survive for long on inanimate surfaces, while coronaviruses are much more stable in the environment (van Doremalen et al., 2020) . Infection control and prevention strategies are designed based on these features. Cough etiquette, hand hygiene and surface decontamination are effective control measures for a virus that is spread by direct contact and large droplets. Preventing airborne spread via droplet nuclei requires use of special measures such as P2/N95 masks or respirators and special air handling. The respiratory epithelium is composed of a variety of cells that include ciliated and non-ciliated epithelial cells, goblet cells that produce mucus that forms the first barrier that an incoming virus and club cells that produce proteases. Different respiratory viruses preferentially bind and infect ciliated or non-ciliated epithelial cells of the airways, pneumocytes lining the alveoli in the lungs and alveolar macrophages (Matrosovich et al., 2004) . For example, avian influenza A viruses infect ciliated epithelial cells while human influenza viruses infect non-ciliated epithelial cells. The presence of specific host cell molecules that are receptors for viral attachment and entry are the main determinants of which cells get infected. Human angiotensin converting enzyme 2 (ACE2) is the receptor for SARS-CoV and SARS-CoV-2 (Zhou et al., 2020) as well as for human coronavirus NL63. The receptor for the Middle East Respiratory Syndrome (MERS) coronavirus is human dipeptidyl peptidase 4 (DPP4) and human coronavirus 229E uses aminopeptidase N as its receptor. All influenza viruses use sialic acid as their receptor but there is an added subtlety; human influenza viruses bind sialic acids with α2,6 -linked oligosaccharides while avian influenza viruses bind sialic acids with α2,3linked oligosaccharides (reviewed in (Paules and Subbarao, 2017) When host cells are infected by viruses, Type I interferon (IFN) and pro-inflammatory cytokines are expressed, cellular translation is suppressed, and an antiviral state is induced. However, many respiratory viruses are able to block IFN activation and/or signalling, and inhibit apoptosis. This prevents the host from effectively clearing virally infected cells and also induces an antiviral state in neighbouring cells, thereby promoting viral replication in infected tissues that may contribute to the observed pathology. When a person is infected with a respiratory virus, there is an incubation period before the onset of clinical signs and symptoms. During the incubation period, the virus attaches to and infects cells, replicates its genome and spreads to infect adjacent cells. The incubation period for influenza is short, typically 1 to 2 days, while for SARS-CoV-2, it is 4.5 to 5.8 days (Lauer et al., 2020) . responses. These responses are initiated by the innate immune system, which recognizes pathogens and induces the production of proinflammatory cytokines and chemokines. This is followed by responses of the adaptive immune system, which consists of T cells that can directly kill virus-infected cells and of B cells that produce pathogen-specific antibodies in the serum and at mucosal surfaces (Chen and Subbarao, 2007) . Innate responses are activated when macrophages encounter either damageassociated molecular patterns (DAMPs) such as intracellular contents released from dying cells or proteins released by tissue injury, or pathogen-associated molecular patterns (PAMPs) such as viral RNA or oxidized phospholipids from invading pathogens. Both DAMPs and PAMPs released during initial infection and lysis of pneumocytes (surface epithelial cells of the alveoli) activate multiple innate immune pathways, through Toll-like receptors (TLRs), NLRP3 and/or inflammasome activation, or triggering of cytoplasmic DNA sensors such as RIG-I-MAVS and cGAS-STING (reviewed in (Vardhana and Wolchok, 2020) ). The signal transduction that follows drives production of cytokines that activate antiviral gene expression programs in neighbouring cells. They also recruit additional innate and adaptive immune cells with diverse roles in antiviral immunity, tissue repair and homeostasis. Dysregulation of the innate immune response contributes to the cytokine storm seen in severe influenza A/H5N1 and SARS-CoV-2 infections. Virus-encoded peptides stimulate activation, proliferation and differentiation of naive CD8 + and CD4 + T cell. Effective viral clearance requires both CD8 + effector T cell-mediated killing of virally infected cells as well as CD4 + T cell-dependent enhancement of CD8 + and B cell responses. Serum immunoglobulin G (IgG) is the dominant antibody involved in protection from respiratory viruses in the lower respiratory tract while mucosal IgA plays an important role in immunity in the upper respiratory tract. While both cellular and humoral responses contribute to the clearance of primary infection, neutralizing antibodies play a critical role in protection against re-infection. Immunological memory is maintained by both T and B cell subsets (Sant and McMichael, 2012) . nonresponsive state known as T-or B cell "exhaustion". This phenotype has been reported in many chronic viral infections and is frequently associated with lymphopenia. In these settings, lung-resident and circulating T cells up-regulate specific markers of T cell exhaustion, such as PD-1 and Tim-3, MKI67 and TYMS (Blank et al., 2019) . Notably, both lymphopenia and T cell exhaustion have been observed in recent viral epidemics caused by SARS and pandemic H1N1 influenza. After an incubation period, infection progresses from the presymptomatic stage (1-3 days), through symptomatic infection (2-4 weeks) to a prolonged post-symptomatic or recovery stage (2-8 weeks) (Figure 2 ). The spectrum of disease with SARS-CoV-2 ranges from asymptomatic infection to severe, often fatal disease. Patients with mild disease (80%) have fever, cough, sore throat, loss of smell, headaches and body aches. Moderate illness is characterised by involvement of the lower respiratory tract. In influenza, the amount of infecting virus (inoculum) correlates with greater severity of infection. It is not yet known whether this is true for SARS-CoV-2; notably, asymptomatic cases of COVID-19 (10-50% of infections) can excrete large quantities of virus (Vardhana and Wolchok, 2020) . Severe infections and complications occur more frequently in males and those with underlying medical conditions (called co-morbidities) including hypertension, diabetes, cardiovascular disease and immunocompromised states. Findings associated with poor outcomes include an increase in white blood cell counts with lymphopenia, a prolonged prothrombin time (indicating coagulopathy), and elevated levels of liver enzymes, lactate dehydrogenase, D-dimer, interleukin-6, C-reactive protein, and procalcitonin (Gandhi et al., 2020) . The pathogenesis of severe SARS-CoV-2 infection is complex and we are still learning about it at the time of this writing. The viral spike glycoprotein binds to the cell surface receptor, angiotensin converting enzyme 2 (ACE2) (Hoffmann et al., 2020) that plays an important regulatory role in the renin-angiotensin-aldosterone system (RAAS). The physiological role of ACE2 is in regulation of blood pressure; ACE2 metabolises angiotensin II which is a vasoconstrictor, to generate angiotensins 1 -7, which are vasodilators. Cells lining the mucosal surfaces of the nose and lungs are endowed with a high concentration of ACE2, that facilitates infection of the respiratory tract. However, ACE2 is also expressed on cells in many other tissues including endothelium, heart, gut, and kidney making these organs susceptible to infection by the virus. A prominent feature of severe SARS-CoV-2 infections is the cytokine release syndrome. SARS-CoV-2 infection of respiratory epithelial cells activates monocytes, macrophages, and dendritic cells, resulting in secretion of a range of proinflammatory cytokines, including IL-6. IL-6 release instigates an amplification cascade that directly results in T helper 17 (Th17) differentiation, among other lymphocytic changes. Circulating IL-6 and soluble IL-6 receptor complexes indirectly activate many cell types including endothelial cells, resulting in a flood of systemic cytokine production that contributes to hypotension and acute respiratory distress syndrome (ARDS). The key role of IL-6 in this cascade has prompted evaluation of IL-6 antagonists such as tocilizumab, sarilumab, and siltuximab for treatment of severe COVID-19 disease (Moore and June, 2020) . In addition to increased vascular permeability, the cytokine "storm" also leads to high levels of fibrinogen and activation of the coagulation cascade on endothelial surfaces of small blood vessels, signalled by very high levels of a fibrin breakdown product called Ddimer. Dysregulation of the RAAS due to competitive binding of ACE2 by the virus may also induce constriction of blood vessels. A puzzling phenomenon has been seen in COVID-19 pneumonia: some patients have extremely low blood oxygen levels, yet they do not complain of breathlessness. It has been suggested that oxygen uptake in COVID-19 pneumonia is impeded because of clogged and constricted blood vessels in the lungs rather than due to congestion from accumulation of edema fluid in the alveoli, as is seen in other viral pneumonias. The benefit of anticoagulants in the treatment of severe COVID-19 disease is therefore of great interest. It is becoming clear that the pathogenetic cascade triggered by SARS-CoV-2 infection damages many organs in the body, from the kidney to the brain. Such pathophysiological changes are rarely seen with other respiratory virus infections. There are no licensed drugs that specifically target SARS-CoV-2 (or other) coronaviruses. The scale of the COVID-19 pandemic, with more than 3 million cases and 230,000 deaths in 185 countries in a 4-month period, has driven an urgent search for drugs with antiviral activity against SARS-CoV-2. The fastest path to finding an effective treatment may be to repurpose licensed drugs that are approved for use in humans for other indications. Drugs that target specific viral proteins or critical host cell processes have been selected for evaluation against SARS-CoV-2 in vitro and in clinical trials (Figure 2 ). More than 300 clinical trials have been registered around the world (listed on Clinicaltrials.gov) but not all are randomized controlled trials (RCTs), which are are the gold standard in clinical research. In RCTs, participants are allocated by chance alone (randomly) to receive an intervention or drug, or one among two or more drugs or interventions; randomization minimizes bias in Immunomodulators may ameliorate severe COVID-19 disease and could be useful as adjuncts to antivirals (Figure 2 ). The cytokine release syndrome and the observation of elevated levels of serum IL-6 and other proinflammatory cytokines in patients with severe COVID-19 has prompted trials of drugs that inhibit the IL-6 pathway such as tocilizumab and sarilumab. Antibodies that can block the infectivity of the virus can be derived from the plasma of recovered patients or from monoclonal antibodies generated from B cells from recovered patients or phage display libraries. Convalescent plasma has been used in SARS and severe influenza (Mair-Jenkins et al., 2015) and COVID-19 in non-randomized trials, alone or as an adjunct to antiviral drugs for treatment of severe disease (Figure 2 ). Antibodies can also be administered to prevent infection in individuals who are known to be at risk of infection (Figure 2 ), referred to as immunoprophylaxis. The optimal timing for administration of antiviral drugs, immunomodulators and therapeutic antibodies should be guided by the phase of the disease and the kinetics of viral replication and immune response (Figure 2 ). pneumonia differs from that caused by the other respiratory viruses in the severity and duration of inflammation that appears to be driven by an exuberant innate immune response, a flood of proinflammatory cytokines and multiorgan dysfunction, driven by derangements in pulmonary and clotting physiology. As the pandemic evolves, we are gaining a better understanding of the complex pathophysiology underlying COVID-19 disease. Treatment strategies currently under study include antiviral agents, immunomodulators, antibodies and adjunctive therapies. (Thevarajan et al., 2020) . The lower panel illustrates optimal timing of potential interventions based on viral and immune kinetics. Immunomodulators are genetically engineered or organism-derived proteins that target specific parts of the immune system. Defining 'T cell exhaustion The Immunobiology of SARS* Mild or Moderate Covid-19 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis Human and avian influenza viruses target different cell types in cultures of human airway epithelium Cytokine release syndrome in severe COVID-19 Revealing the role of CD4(+) T cells in viral immunity Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 The many faces of the anti-COVID immune response Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial A pneumonia outbreak associated with a new coronavirus of probable bat origin The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health.